Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients

Tzortzatos,Gerasimos; Aravidis,Christos; Lindblom,Annika; Mints,Miriam; Tham,Emma

doi:10.3892/ol.2015.2890

Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients

Authors:
- Gerasimos Tzortzatos
- Christos Aravidis
- Annika Lindblom
- Miriam Mints
- Emma Tham
View Affiliations

Affiliations: Department of Women's and Children's Health, Division of Obstetrics and Gynecology, The Karolinska Institute, Karolinska University Hospital, Solna, Stockholm 171 76, Sweden, Department of Clinical Genetics, Akademiska Hospital, Uppsala University, Uppsala 751 85, Sweden, Department of Clinical Genetics, The Karolinska Institute, Karolinska University Hospital, Solna, Stockholm 171 76, Sweden
Published online on: January 23, 2015 https://doi.org/10.3892/ol.2015.2890
Pages: 1782-1786

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cowden syndrome (CS) is an autosomal dominant disorder characterized by multiple hamartomas in the breast, thyroid and endometrium, with a prevalence of 1 per 250,000. Females with CS have a 21‑28% lifetime risk of developing uterine cancer. Germline mutations in the phosphatase and tensin homolog (PTEN) gene, a tumor suppressor gene, are responsible for 30‑80% of CS cases. PTEN is a nine‑exon gene, located on chromosome 10q23.3, which encodes the 403 amino acid PTEN protein. It negatively regulates the phosphoinositide 3‑kinase/protein kinase B/mammalian target of rapamycin pathway, affecting various cellular processes and signaling pathways. The present study examined whether PTEN mutations are present in CS‑like families with uterine cancer (UC). UC patients underwent surgery at Karolinska University Hospital, Stockholm, Sweden (2008‑2012). Pedigrees were analyzed and 54 unrelated CS‑like families were identified. CS‑like families were defined as having at least one occurrence of uterine cancer and one of breast cancer, as well as at least one additional Cowden‑associated tumor (uterine, breast, thyroid, colon or kidney cancer) in the same individual or in first‑degree relatives. Genomic DNA was amplified using polymerase chain reaction, and DNA sequencing analysis of all nine exons of the PTEN gene was conducted. No germline PTEN mutations or polymorphisms were identified. Germline PTEN mutations are rare in CS‑like families with uterine cancer, therefore, genetic screening must be restricted to patients that meet the strict National Comprehensive Cancer Network criteria. Gynecologists must be aware of the CS criteria and identify potential cases of CS in females where uterine cancer is the sentinel cancer.

View Figures

View References

1	Cancer incidence in Sweden in 2011. National Board of Health and Welfare; Stockholm, Sweden: pp. 23–25. 2012
2	Haidopoulos D, Simou M, Akrivos N, Rodolakis A, Vlachos G, et al: Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand. 89:1326–1330. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sorosky JI: Endometrial cancer. Obstet Gynecol. 120:383–397. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 16:8–13. 2009.
5	Black D, Bogomolniy F, Robson ME, Offit K, Barakat RR and Boyd J: Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol. 96:21–24. 2005. View Article : Google Scholar
6	Peterson LM, Kipp BR, Halling KC, et al: Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol. 31:195–205. 2012. View Article : Google Scholar : PubMed/NCBI
7	Olson SH, Chen C, De Vivo I, Doherty JA, Hartmuller V, et al: Maximizing resources to study an uncommon cancer: E2C2 - Epidemiology of Endometrial Cancer Consortium. Cancer Causes Control. 20:491–496. 2009. View Article : Google Scholar : PubMed/NCBI
8	Farooq A, Walker LJ, Bowling J and Audisio RA: Cowden syndrome. Cancer Treat Rev. 36:577–583. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM and Swisher E: Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 105:1607–1616. 2013. View Article : Google Scholar : PubMed/NCBI
10	Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al: Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer. 13:57–63. 2014. View Article : Google Scholar
11	Bubien V, Bonnet F, Brouste V, et al; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 50:255–263. 2013. View Article : Google Scholar : PubMed/NCBI
12	Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS and Eng C: Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 18:400–407. 2012. View Article : Google Scholar : PubMed/NCBI
13	National Comprehensive Cancer Network. NCCN guidelines, version 1.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 25, 2012
14	Orloff MS and Eng C: Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene. 27:5387–5397. 2008. View Article : Google Scholar : PubMed/NCBI
15	Marsh DJ, Dahia PL, Caron S, et al: Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 35:881–885. 1998. View Article : Google Scholar : PubMed/NCBI
16	Rustad CF, Bjørnslett M, Heimdal KR, Mæhle L, Apold J and Møller P: Germline PTEN mutations are rare and highly penetrant. Hered Cancer Clin Pract. 4:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
17	Lynch ED, Ostermeyer EA, Lee MK, et al: Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet. 61:1254–1260. 1997. View Article : Google Scholar : PubMed/NCBI
18	Freihoff D, Kempe A, Beste B, et al: Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 79:754–758. 1999. View Article : Google Scholar : PubMed/NCBI
19	Kurian AW, Hare EE, Mills MA, et al: Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 32:2001–2009. 2014. View Article : Google Scholar : PubMed/NCBI
20	Castéra L, Krieger S, Rousselin A, et al: Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 22:1305–1313. 2014. View Article : Google Scholar : PubMed/NCBI
21	Laugé A, Lefebvre C, Laurent-Puig P, et al: No evidence for germline PTEN mutations in families with breast and brain tumours. Int J Cancer. 84:216–219. 1999. View Article : Google Scholar : PubMed/NCBI
22	Nagy R, Ganapathi S, Comeras I, et al: Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 21:505–510. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhou XP, Waite KA, Pilarski R, et al: Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet. 73:404–411. 2003. View Article : Google Scholar : PubMed/NCBI
24	Bennett KL, Mester J and Eng C: Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 304:2724–2731. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ni Y, Zbuk KM, Sadler T, et al: Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 83:261–268. 2008. View Article : Google Scholar : PubMed/NCBI
26	Orloff MS, He X, Peterson C, et al: Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet. 92:76–80. 2013. View Article : Google Scholar :
27	Ngeow J, Ni Y, Tohme R, Song Chen F, Bebek G and Eng C: Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer. J Clin Endocrinol Metab. 99:E1316–E1321. 2014. View Article : Google Scholar : PubMed/NCBI